Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 10 of 10 entries
View as:

A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)

Phase: N/A Priority: Normal
NCT ID: NCT03987295 Org: User:
Start: 09/27/19 End: 06/05/24 Due: 06/05/25

First in Human Study for Safety and Tolerability of AL003.

Phase: N/A Priority: Normal
NCT ID: NCT03822208 Org: User:
Start: 03/29/19 End: 05/06/21 Due: 05/06/22

A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS

Phase: N/A Priority: Normal
NCT ID: NCT05053035 Org: User:
Start: 09/02/21 End: 10/28/22 Due: 10/28/23

A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT04592874 Org: User:
Start: 01/22/21 End: 09/12/24 Due: 09/12/25

A Phase I Study for Safety and Tolerability of AL002.

Phase: N/A Priority: Normal
NCT ID: NCT03635047 Org: User:
Start: 11/12/18 End: 11/25/20 Due: 11/25/21

A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05744401 Org: User:
Start: 01/04/23 End: 01/31/25 Due: 01/31/26

A Phase 1 First in Human Study to Assess Safety and Tolerability of AL101

Phase: N/A Priority: Normal
NCT ID: NCT04111666 Org: User:
Start: 12/14/19 End: 06/09/22 Due: 06/09/23

A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation

Phase: N/A Priority: Normal
NCT ID: NCT03636204 Org: User:
Start: 09/14/18 End: 12/31/19 Due: 12/31/20

A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)

Phase: N/A Priority: Normal
NCT ID: NCT04374136 Org: User:
Start: 07/23/20 End: 08/03/27 Due: 08/03/28

Continuation Study for Latozinemab

Phase: N/A Priority: Normal
NCT ID: NCT06111014 Org: User:
Start: 12/08/23 End: 11/30/27 Due: 11/30/28